News: Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

56.51USD
5 Mar 2015
Change (% chg)

$-0.05 (-0.09%)
Prev Close
$56.56
Open
$56.60
Day's High
$56.94
Day's Low
$56.40
Volume
645,952
Avg. Vol
816,333
52-wk High
$61.90
52-wk Low
$47.37

Search Stocks
Select another date:

Wed, Mar 4 2015

BRIEF-U.S. judge for Teva in patent litigation concerning Atelvia

March 4 - * U.S. judge rules in favor of Teva Pharmaceutical Industries Ltd and

Appeals court rules for Lupin, against Teva over generic HIV drugs

- The top U.S. patent appeals court has affirmed a district court decision allowing generic drugmaker Lupin Ltd, but not Teva Pharmaceuticals, to make generic versions of ViiV Healthcare Co's HIV drugs.

Teva's internal investigation finds possible corruption

- Israeli drugmaker Teva Pharmaceutical Industries Inc said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.

Teva's internal investigation finds possible corruption

Feb 11 - Israeli drugmaker Teva Pharmaceutical Industries Inc said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.

Israeli drugmaker Teva eyes acquisitions after year of cuts

TEL AVIV - Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive.

UPDATE 1-Israeli drugmaker Teva eyes acquisitions after year of cuts

* Teva seeks growth markets, complex generics, specialty drugs

BRIEF-Teva Pharm CEO on generic Copaxone in 2015

* There might not be any generic Copaxone competition in 2015 but we assume there may be -CEO Further company coverage: (Reporting By Steven Scheer)

BRIEF-Teva Pharm plans 7 drug launches in 2015

* Plans 7 drug launches in 2015 with $400 million of new revenue -CEO Further company coverage: (Reporting By Tova Cohen)

Teva Pharm Q4 profit, revenue meet expectations

TEL AVIV, Feb 5 - Teva Pharmaceutical Industries reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year.

FDA approves Teva's generic version of AstraZeneca's Nexium

- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.

Select another date:
Search Stocks